Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Ombow, Thanks. >> the Data and Safety

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
gfp927z Member Profile
 
Followed By 61
Posts 22,805
Boards Moderated 73
Alias Born 03/22/05
160x600 placeholder
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 9/15/2020 5:06:59 PM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 9/14/2020 4:31:44 PM
SA Breaking News: ALYI - Alternet Systems revenue surging with new potential customers InvestorsHub NewsWire - 9/14/2020 10:10:04 AM
Traders News Source Identifies Tomorrows NASDAQ's InvestorsHub NewsWire - 9/3/2020 8:45:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 9/1/2020 5:34:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/1/2020 2:57:56 PM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 9/1/2020 1:47:41 PM
MICROCAP DAILY - The Exciting Story of Puration Inc (OTCMKTS: PURA) InvestorsHub NewsWire - 8/26/2020 9:02:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/18/2020 4:31:34 PM
Annual Report (10-k) Edgar (US Regulatory) - 8/14/2020 5:19:57 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2020 5:21:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 4:34:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/8/2020 5:07:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 4:31:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2020 5:19:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 7:24:49 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 6/8/2020 5:28:53 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/8/2020 6:02:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 5:01:56 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/2/2020 8:01:17 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 5/15/2020 8:47:08 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2020 6:00:59 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 4/30/2020 5:28:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 5:29:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2020 5:03:47 PM
gfp927z   Monday, 07/13/20 09:13:35 PM
Re: ombowstring post# 93816
Post # of 118738 
Ombow, Thanks. >> the Data and Safety Monitoring Committee will be looking into the trial with results hopefully known in July <<


I think that will mainly focus on the safety aspects of the drug, not so much to assess efficacy, and they won't actually release 'results' at that time, but merely allow the trial to continue or not continue.

Sometimes they stop trials for toxicity reasons (very unlikely with Leronlimab), or when there is no sign of efficacy at all. In CYDY's case the Data and Safety Monitoring Committee will likely allow the trial to continue to completion, but we won't see any actual data/results made public.

An interim analysis is what we need. My concern would be if the mild/moderate trial disappoints next week, then investors don't want to wait too long for data from the severe trial. Since Leronlimab works at the cytokine storm level, the severe trial 'should' be the best chance to show good efficacy (theoretically).





Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences